Organisation paid for research Program year 2021 Source: CMS Open Payments

Cherry Street Services Inc

Neither a doctor nor a teaching hospital

Research payments

$132,831

56 payments

Through program year 2021, Cherry Street Services Inc is reported as receiving $132,831 in research payments, across 56 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $5,681 3
2020 Research $33,517 30
2019 Research $93,634 23

Breakdown

Who paid Research payments · program years 2019–2021
  1. Biogen, Inc. $47,499 1 payment
  2. Janssen Research & Development, LLC $37,685 19 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $31,716 24 payments
  4. Neurocrine Biosciences, Inc. $12,205 5 payments
  5. Alkermes, Inc. $3,727 7 payments
Studies the money was for Research payments · program years 2019–2021
  1. A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $47,499 1 payment
  2. A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of Tak-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia $28,035 22 payments
  3. A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation $20,349 8 payments
  4. A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics $17,336 11 payments
  5. Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $6,500 2 payments
  6. Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 $3,727 7 payments
  7. Charisma $3,705 2 payments
  8. A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of Tak-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia $3,681 2 payments
  9. A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia $2,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record